[Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors

Objective

To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.

Method

Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.

Results

Forty-one patients were included: 65% male, median age 54 years (SD = 13). The included patients were treated with ixekizumab 35%, guselkumab 25%, secukinumab 17.5%, brodalumab 15%, and risankizumab 7.5%.

Psoariasis area severity index (PASI) reduction was 94.6% (RIC 76.8–100%), DLQI of 1 (RIC 0–2.75), DLQI ≤ 1 60%. The most affected health dimensions were symptoms and perceptions (57.5%), activities of daily living (27.5%), and discomfort caused with treatment (17.5%). No association was found between DLQI score < 1 and demographic, comorbidities, and treatment-related variables. The median PASI reduction in patients with DLQI < 1 was superior to patients with DLQI > 1 (100% vs 90.2%, p = .025).

Conclusions

Patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors achieve adequate therapeutic targets achieving the target set according to clinical practice guideline recommendations (score ≤ 1 on the DLQI questionnaire and 90–100% reduction in the PASI index) and in accordance with the results of recent meta-analyses and real-life studies.

A greater reduction of the PASI index is observed in the group reaching the quality of life target, there being the possibility of using patient-reported outcomes in the evaluation of treatment effectiveness.